BeOne Medicines (BEIGF) Accounts Payables (2015 - 2026)

BeOne Medicines (BEIGF) has reported Accounts Payables for 12 consecutive years, with $470.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Accounts Payables rose 30.36% year-over-year to $470.3 million in Q2 2026; TTM through Jun 2026 was $470.3 million, a 30.36% increase from a year earlier, with the FY2025 full-year figure at $479.0 million, up 18.28% from the prior year.
• Accounts Payables was $470.3 million for Q2 2026 at BeOne Medicines, up from $423.5 million in the prior quarter.
• Over five years, Accounts Payables peaked at $479.0 million in Q4 2025 and troughed at $234.4 million in Q2 2022.
• A 5-year average of $337.1 million and a median of $337.4 million in 2023 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables surged 61.25% in 2022 and slipped 10.04% in 2024, its largest moves.
• Over 5 years, Accounts Payables stood at $294.8 million in 2022, then gained by 6.9% to $315.1 million in 2023, then rose by 28.53% to $405.0 million in 2024, then gained by 18.28% to $479.0 million in 2025, then dropped by 1.82% to $470.3 million in 2026.
• The last three Accounts Payables figures came in at $470.3 million (Q2 2026), $423.5 million (Q1 2026), and $479.0 million (Q4 2025), per Business Quant data.